Bryn Pharma is developing a needle-free epinephrine nasal spray for the emergency treatment of anaphylaxis, addressing the challenges of current bulky autoinjectors that many patients are reluctant to use or carry. This portable and easy-to-administer device aims to improve accessibility and compliance for individuals at risk of severe allergic reactions.
Funding
$122.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current epinephrine autoinjectors for anaphylaxis are often bulky and needle-based, leading to reluctance or inability to carry and administer them, resulting in delayed or untreated allergic reactions. Many individuals at risk do not carry their medication due to size and usability concerns.
Solution
Bryn Pharma is developing NDS1C, a needle-free epinephrine nasal spray designed for the emergency treatment of anaphylaxis. This compact and user-friendly device aims to improve accessibility and compliance by offering a more convenient alternative to traditional autoinjectors. The nasal spray formulation eliminates the need for injections, addressing needle phobias and simplifying administration in emergency situations. Bryn Pharma's mission is to provide an affordable and easily portable solution that empowers individuals to manage their risk of anaphylaxis effectively.
Target Audience
The primary target audience includes individuals at risk of anaphylaxis, their caregivers, and healthcare providers seeking a more accessible and convenient epinephrine delivery method.
Features
- Needle-free nasal spray delivery system for epinephrine
- Compact and portable design for easy carrying
- Simplified administration process, requiring no special medical training
- Unit dose spray